Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL719304 | 0.99 | ALOX15 (0.38) | ALOX15ALDH1A1GAAL3MBTL1TEAD4 | |
| SCHEMBL719424 | 0.94 | TEAD4 (0.37) | ALOX15ALDH1A1L3MBTL1TEAD4PTGDR2 | |
| SCHEMBL720867 | 0.90 | KMT2A (0.34) | ALDH1A1L3MBTL1TEAD4TP53TSHR | |
| SCHEMBL718844 | 0.88 | KDM4E (0.38) | ALDH1A1L3MBTL1MAOBTSHR | |
| SCHEMBL721953 | 0.88 | DGAT1 (0.36) | L3MBTL1TEAD4TSHR | |
| SCHEMBL721591 | 0.88 | TP53 (0.42) | ALDH1A1TP53 | |
| SCHEMBL718770 | 0.87 | KMT2A (0.35) | ALDH1A1TEAD4TP53TSHR | |
| SCHEMBL718427 | 0.87 | KMT2A (0.35) | ALDH1A1GAATEAD4TP53TSHR | |
| SCHEMBL719968 | 0.87 | NPC1 (0.38) | ALDH1A1L3MBTL1TEAD4CA12CA9 | |
| SCHEMBL718598 | 0.87 | KMT2A (0.33) | ALDH1A1TEAD4TP53TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053173-A1 | HETEROCYCLIC COMPOUND | SLC5A2, SLC5A1, IAPP | ALOX15 1082/4885ALDH1A1 504/4885GAA 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.